Thanks @stockrock.
Interesting to see that Morningstar appears not to have heeded Silviu's very clear statement in the latest conf call that MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy is considered by MSB to be their best revenue prospect. (Morningstar - "We are not changing our assessment of other clinical programs currently in train and continue to view the lead MPC-150-IM program in advanced chronic heart failure as the key driver of value for Mesoblast.)
I think that what Silviu is referring to is that while CHF might be a bigger market than R.A., a successful treatment for R.A. could very likely be extended to the huge market of immune-mediated and inflammatory conditions. Success there would really put a bit of life into this board's $100 plus musings.
Morningstar $2.10 valuation, page-2
-
- There are more pages in this discussion • 81 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |